[ij] [ij] [ij] 
Email id

Asian Journal of Pharmacy and Technology
Year : 2019, Volume : 9, Issue : 4
First page : ( 267) Last page : ( 270)
Print ISSN : 2231-5705. Online ISSN : 2231-5713.
Article DOI : 10.5958/2231-5713.2019.00044.8

A Review on Biopharmaceutical Classification System

Saxena Swati*, Dr. Jain Sarang

Rajeev Gandhi College of Pharmacy, Bhopal, India

*Corresponding Author E-mail: sweeto2586@gmail.com

Online published on 31 December, 2019.


The biopharmaceutical classification system (BCS) is the result of continuous effort in the mathematical analysis. By this process we can assume kinetics and dynamics of drug in gastrointestinal tract. This process reduces time required to develop a new drug. FDA has published Biopharmaceutical Classification System in order to guide pharmaceutical companies regarding how product qualifies for biowaivers. This can be achieved by avoiding expensive in vivo bioavailability and bioequivalence studies. It helped pharmaceutical companies for easy application of NDA (New drug Application) and ANDA (Abbreviated new drug application) by combining data of drug's aqueous solubility as well as in vitro dissolution drug release data. The main objective of this article is to make all researchers understand the concept of Biopharmaceutical classification system of drug in a simple manner. So that they can make use of this knowledge in their research work by reducing time in identifying best drug for their formulation.



Biopharmaceutical Classification System, solubility, permeability, dissolution, bioequivalence, immediate-release products.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
742,745,465 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.